Purchase this article with an account.
Maribel La Fontaine, Fadi S Shaya, Kent W Small; Ocriplasmin (Jetrea) and Its Effects on Photoreceptor Function. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4883.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Intravitreal injections of Ocriplasmin (Jetrea) have recently been used to treat vitreo-macular traction (VMT). Associated with these injections, some have reported transient dyschromatopsias and electroretinography (ERG) abnormalities. We reviewed our experience with Ocriplasmin including ERG findings.
A retrospective chart review was conducted of our first 4 patients who were treated with intravitreal injections of Ocriplasmin. Data collected were Snellen visual acuity, funduscopy, fundus photographs,OCT (optical coherence tomography) and IVFA (fluorescein angiography) findings before and after Ocriplasmin intravitreal injection. The photoreceptor function was evaluated using ISEV standard ERG testing.
One of the four subjects had successful release of the vitreo-macular traction and closure of the macular hole. This patient also had moderate loss of rod function by ERG which has persisted for at least 6 months. Of the remaining subjects whose injection was unsuccessful in releasing the VMT, no significant photoreceptor changes were noted by ERG.
Ocriplasmin can cause loss of rod function on ERG testing which can be long lasting. This ERG change occurred in the only subject who had successful release of VMT. This is one of the first reported ERG changes in patients treated with Ocriplasmin.
This PDF is available to Subscribers Only